kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human CTLA4/CD152 Protein, His Tag, 100µg  

Recombinant human CTLA4/CD152 Protein, His Tag, 100µg

Recombinant Human CTLA4 /CD152 Protein (rhCTLA4) Ala 37 - Phe 162, produced in human 293 cells (HEK293), His Tag

recombinant human protein CTLA4, CD152

More details


Availability: within 7 days

182,00 €

CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) is also known as CD152 (Cluster of differentiation 152), is a protein receptor that downregulates the immune system. CTLA4 is a member of the immunoglobulin superfamily, which is expressed on the surface of Helper T cells and transmits an inhibitory signal to T cells. The protein contains an extracellular V domain, a transmembrane domain, and a cytoplasmic tail. Alternate splice variants, encoding different isoforms. CTLA4 is similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA4 is also found in regulatory T cells and may be important to their function. T cell activation through the T cell receptor and CD28 leads to increased expression of CTLA-4, an inhibitory receptor for B7 molecules. Fusion proteins of CTLA4 and antibodies (CTLA4-Ig) have been used in clinical trials for rheumatoid arthritis.

Recombinant Human CTLA4 /CD152 Protein (rhCTLA4), His Tag (CT4-H5229) is expressed from human 293 cells (HEK293). It contains AA Ala 37 - Phe 162 (Accession # P16410-1).
Predicted N-terminus: Ala 37

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 15.4 kDa. The protein migrates as 20-25 kDa under reducing (R) condition (SDS-PAGE) due to different extent glycosylation.

Less than 1.0 EU per μg by the LAL method.

>95% purity as determined by SDS-PAGE.

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 6 months under sterile conditions after reconstitution.

Please refer to product data sheet.

Clinical and Translational Updates

(1) Clinical characterization and treatment outcomes of follicular cutaneous immune-related adverse events caused by immune checkpoint inhibitors: a multicenter retrospective study
Freites-Martinez, Nikolaou, Lallas et al
J Am Acad Dermatol (2022)
(2) "Modulation of the intestinal microbiota impacts the efficacy of immunotherapy in cancer patients - A recent literature survey
Ziegler, Bereswill, Heimesaat
Eur J Microbiol Immunol (Bp) (2022)
(3) Improvement of the sepsis survival rate by adenosine 2a receptor antagonists depends on immune regulatory functions of regulatory T-cells
Zhang, Zhao, Fu et al
Front Immunol (2022) 13, 996446
Showing 1-3 of 11971 papers.


Authors: C Beil, K Engel, G Hessler, et al.
Journal: US20200255540A1 2020
Application: SPR
(2) "Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR"
Authors: Simons JF, Lim YW, Carter KP, et al
Journal: Mabs 2020
Application: Flow cytometry
(3) "Comprehensive in vitro characterization of PD-L1 small molecule inhibitors"
Authors: Ganesan A, et al
Journal: Sci Rep 2019
Application: SPR
(4) "Therapeutic monoclonal antibodies in human breast milk: a case study"
Authors: Ross E, et al.
Journal: Melanoma Res 2014
Application: ELISA